Zhiyuan Ran - LakeShore Biopharma Head Department
| LSBPW Stock | 0.05 0 4.19% |
Executive
Zhiyuan Ran is Head Department of LakeShore Biopharma Co,
| Address | Building No. 2, Beijing, China, 102629 |
| Phone | 86 10 8920 2086 |
| Web | https://www.ysbiopharm.com |
LakeShore Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1385) % which means that it has lost $0.1385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6599) %, meaning that it generated substantial loss on money invested by shareholders. LakeShore Biopharma's management efficiency ratios could be used to measure how well LakeShore Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.59 in 2025. At this time, LakeShore Biopharma's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 10.1 M in 2025, whereas Total Assets are likely to drop slightly above 944.3 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Balser | Major Drilling Group | N/A | |
| Roddie Mackenzie | Transocean | N/A | |
| Matthew Bley | CVR Energy | 38 | |
| George JD | Asbury Automotive Group | 57 | |
| Thomas Moriarty | Albertsons Companies | 61 | |
| Robert Larson | Albertsons Companies | 54 | |
| Mike Puddy | CVR Energy | N/A | |
| Ian Ross | Major Drilling Group | N/A | |
| Steve JD | Titan Machinery | N/A | |
| Robert Vayda | Transocean | 62 | |
| Andrew McLaughlin | Major Drilling Group | N/A | |
| Lexington May | Transocean | N/A | |
| B Mgt | Transocean | 49 | |
| Brady JD | Transocean | 52 | |
| Sandro Thoma | Transocean | N/A | |
| Roderick Mackenzie | Transocean | 49 | |
| Jason Anderson | Titan Machinery | N/A | |
| Douglas Johnson | CVR Energy | 59 | |
| Paul Johnson | Transocean | N/A | |
| David Keddington | Transocean | N/A | |
| Shane Dorcheus | Albertsons Companies | N/A | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.14 |
LakeShore Biopharma Co, Leadership Team
Elected by the shareholders, the LakeShore Biopharma's board of directors comprises two types of representatives: LakeShore Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LakeShore. The board's role is to monitor LakeShore Biopharma's management team and ensure that shareholders' interests are well served. LakeShore Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LakeShore Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dave Chenn, CoCEO Board | ||
| CFA MBA, President Officer | ||
| Yuan Liu, Head Research | ||
| MS MBA, Interim Director | ||
| Zenaida MD, Chief Officer | ||
| Gang Li, Head Sales | ||
| Zhiyuan Ran, Head Department | ||
| Wang Xu, Chief Officer |
LakeShore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LakeShore Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.69) % | ||||
| Number Of Shares Shorted | 17.41 K | ||||
| Revenue | 573.42 M | ||||
| Gross Profit | 386.06 M | ||||
| EBITDA | (368.66 M) | ||||
| Net Income | (433.46 M) | ||||
| Total Debt | 424.46 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LakeShore Stock Analysis
When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.